Mediolanum International Funds Ltd Has $1.55 Million Stake in Hologic, Inc. (NASDAQ:HOLX)

Mediolanum International Funds Ltd decreased its stake in shares of Hologic, Inc. (NASDAQ:HOLXFree Report) by 4.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 21,531 shares of the medical equipment provider’s stock after selling 898 shares during the period. Mediolanum International Funds Ltd’s holdings in Hologic were worth $1,552,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Wolff Wiese Magana LLC acquired a new position in shares of Hologic during the 3rd quarter valued at about $25,000. General Partner Inc. acquired a new stake in Hologic in the 4th quarter valued at approximately $26,000. First Horizon Advisors Inc. grew its holdings in Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 134 shares during the last quarter. Cromwell Holdings LLC grew its holdings in Hologic by 330.2% in the 3rd quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock valued at $44,000 after buying an additional 416 shares during the last quarter. Finally, Covestor Ltd grew its holdings in Hologic by 23.8% in the 3rd quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock valued at $56,000 after buying an additional 133 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Price Performance

Hologic stock opened at $72.14 on Monday. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. The company has a market capitalization of $16.28 billion, a PE ratio of 21.66, a price-to-earnings-growth ratio of 2.33 and a beta of 0.97. Hologic, Inc. has a one year low of $68.61 and a one year high of $84.67. The business has a 50 day simple moving average of $73.35 and a 200 day simple moving average of $78.07.

Hologic (NASDAQ:HOLXGet Free Report) last issued its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The firm had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. During the same quarter in the previous year, the company posted $0.89 EPS. The business’s revenue for the quarter was up 4.5% compared to the same quarter last year. On average, sell-side analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Insider Buying and Selling at Hologic

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the transaction, the chief operating officer now owns 27,957 shares in the company, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.88% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on HOLX shares. Mizuho lowered their target price on Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a report on Tuesday, November 5th. Royal Bank of Canada raised their target price on Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a report on Tuesday, November 5th. JPMorgan Chase & Co. lifted their price objective on Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Raymond James lifted their price objective on Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a report on Tuesday, November 5th. Finally, Needham & Company LLC reissued a “buy” rating and set a $90.00 price objective on shares of Hologic in a report on Monday, January 13th. Seven analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $88.92.

Check Out Our Latest Research Report on HOLX

About Hologic

(Free Report)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

See Also

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLXFree Report).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.